Advertisement

Advertisement
Miriam Knoll, MD, and Richard J. White, DO, on Non–Small Cell Lung Cancer: Predicting Radiotherapy/Immunotherapy Treatment Outcomes

Miriam Knoll, MD, and Richard J. White, DO, on Non–Small Cell Lung Cancer: Predicting Radiotherapy/Immunotherapy Treatment Outcomes

Long-Term Results of Standard- vs High-Dose Chemoradiotherapy With or Without Cetuximab in Patients With Stage III NSCLC

Long-Term Results of Standard- vs High-Dose Chemoradiotherapy With or Without Cetuximab in Patients With Stage III NSCLC

As reported in the Journal of Clinical Oncology by Jeffrey D. Bradley, MD, and colleagues, long-term results of the phase III NRG Oncology/RTOG 0617 trial indicate that standard-dose radiotherapy should remain the standard of care in chemoradiotherapy for nonresectable stage III non–small cell lung cancer (NSCLC). The addition of cetuximab to treatment provided no survival benefit.

Pembrolizumab in KRAS-Mutant and Wild-Type PD-L1–Positive Nonsquamous NSCLC

Pembrolizumab in <em>KRAS</em>-Mutant and Wild-Type PD-L1–Positive Nonsquamous NSCLC

In an analysis reported in Annals of Oncology, Roy S. Herbst, MD, PhD, and colleagues found that pembrolizumab was active in both KRAS-mutant and wild-type tumors in a subgroup of patients in the KEYNOTE-042 trial with programmed cell death ligand 1 (PD-L1)-positive nonsquamous non–small cell lung cancer (NSCLC). The phase III trial showed that first-line pembrolizumab improved overall survival vs platinum-based chemotherapy among all patients with PD-L1–positive (tumor proportion score ≥ 1%) NSCLC. 

Osimertinib in Patients With NSCLC Harboring Uncommon EGFR Mutations

In a Korean phase II study reported in the Journal of Clinical Oncology, Myung-Ju Ahn, MD, PhD, and colleagues found that osimertinib was active in patients with metastatic or recurrent non–small cell lung cancer (NSCLC) with uncommon EGFR mutations.

Step Counts May Help Predict Treatment Outcomes for Patients With NSCLC

A new study suggests step counters could play a role in predicting outcomes for people undergoing chemoradiation therapy for lung cancer. These findings were published by Ohri et al in the International Journal of Radiation Oncology • Biology • Physics.

Erlotinib Plus Ramucirumab: Ready for Prime Time?

Erlotinib Plus Ramucirumab: Ready for Prime Time?

The treatment of epidermal growth factor receptor (EGFR)-positive lung cancer changed dramatically after the results of the FLAURA trial showed improved progression-free survival with the third-generation EGFR tyrosine kinase inhibitor osimertinib as first-line therapy compared with earlier-generation tyrosine kinase inhibitors (erlotinib and gefitinib). Further follow-up confirmed longer overall survival for patients in the osimertinib arm (38.6 vs 31.8 months).

Advertisement


Advertisement